Doxycycline Postexposure Prophylaxis (PEP) Archives

Doxy-PEP Lowers Syphilis Cases, Directing More Care Toward Pregnant Women

An analysis of surveillance data from January 2017–June 2025 in Washington’s King County area found a health clinic program that offered doxycycline post-exposure prophylaxis (doxy-PEP) starting in March 2023 was associated with substantial declines in syphilis diagnoses. Compared with projected trends, researchers found total cases decreased by 52.3% (3,031 fewer cases), as published in Clinical Infectious Diseases. Reductions were greatest among cisgender men (−53.1%; 2,248 fewer cases) but were also observed in cisgender women (−46.9%; …

Doxy PEP Demonstrates Real-World Effectiveness

A study of 2,083 patients found that doxycycline postexposure prophylaxis (doxy PEP) was highly effective in preventing sexually transmitted infections (STIs) in a real-world setting. Conducted from April 2019 to July 2024 at the Los Angeles LGBT Center, the study analyzed patient demographics, STI testing history, and doxy PEP use patterns. Nearly half of participants were aged 31–40, over half were White, and most (85.2%) were gay or bisexual men. Most were not diagnosed with …

Study Shows Doxy PEP Did Not Reduce STIs

A study published in the New England Journal of Medicine represents the first clinical trial to test whether doxycycline postexposure prophylaxis (PEP) would prevent sexually transmitted infections (STIs) among cisgender women. Researchers considered 224 subjects assigned to a doxycycline-PEP group and 225 to a standard-care group over 12 months. A total of 109 incident STIs occurred: 50 in the doxycycline-PEP group and 59 in the standard-care group. Chlamydia accounted for 85 of the STIs (78%) with 35 …

Login to JUCM